Guggenheim Initiates Coverage On Neumora Therapeutics with Buy Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja has initiated coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and a price target of $22.
October 10, 2023 | 9:54 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim has initiated coverage on Neumora Therapeutics with a Buy rating and a price target of $22.
The initiation of coverage by Guggenheim with a Buy rating indicates a positive outlook for Neumora Therapeutics. The price target of $22 suggests that the analyst believes the stock has significant upside potential. This is likely to have a positive impact on the stock in the short term as it may increase investor confidence and demand for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100